For Research Purposes Only

PurePeptideHub
weight-lossapproved

Tirzepatide

Tirzepatide (Mounjaro/Zepbound)

Overview

A dual GIP/GLP-1 receptor agonist approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). Shows superior weight loss results compared to semaglutide in trials.

Mechanism of Action

Activates both GIP and GLP-1 receptors, providing dual hormone action. This combination may provide enhanced metabolic benefits compared to GLP-1 alone.

Popular Research Uses

  • Weight loss (up to 22% body weight in trials)
  • Diabetes management
  • Appetite control
  • Metabolic health

Potential Side Effects

  • Nausea and vomiting
  • Diarrhea
  • Decreased appetite
  • Abdominal pain
  • Constipation

Warnings

  • Requires prescription
  • Supply shortages common
  • Similar risks to semaglutide
  • Higher cost than semaglutide
  • Limited long-term data

Dosage Information

Gradual dose escalation required. Higher doses show greater weight loss.

Research Sources

Disclaimer: This content is for research and educational purposes only. Tirzepatide is not approved for human consumption. Always consult with qualified healthcare professionals before making any decisions related to peptide research.